N
Nested Therapeutics
Aims to advance precision oncology medicine by finding new driver mutations hiding in plain sight
About Nested Therapeutics
Nested Therapeutics is a startup operating in the precision oncology medicine market. The company is focused on identifying new driver mutations, which are changes in genes that can lead to cancer, that have been overlooked by current medical approaches. By doing so, Nested Therapeutics aims to broaden the reach of precision medicine, a form of medical treatment that uses genetic understanding to tailor therapies to individual patients.
Read full description
The company's business model revolves around its proprietary drug discovery platform. This platform uses a combination of genomics, computational biophysics, machine learning, and chemical biology to identify potential targets for new therapeutics. In simpler terms, they use a mix of biology, computer science, and chemistry to find new ways to treat cancer.
Nested Therapeutics makes money by developing and commercializing these new therapeutics. Their lead program, NEST-1, is a drug that targets multiple components in a specific pathway that can lead to cancer. This drug is designed to be non-degrading, meaning it remains effective for a longer period of time.
The company's clients are primarily patients with advanced, metastatic cancer. Currently, less than 1% of these patients are eligible for existing precision medicines, indicating a significant market opportunity for Nested Therapeutics.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Cambridge, United States
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 68.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Nested Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Oct 2022 | $90M | $360M | Section 32 · Avidity Partners · Cowen Healthcare Investments · Foresite Capital | ↗ |
| SEEDOther financing | Jan 2022 | $35M | $140M | Versant Ventures | ↗ |
Growth signals
Latest recorded traffic for Nested Therapeutics is 1.1K monthly website visits, down 56% over the last three months. Nested Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A5 investors entered at this stage
Goldman Sachs Asset Management
Section 32
Avidity Partners- CICowen Healthcare Investments
Foresite Capital
Other known investors1 additional known investor
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nested Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nested Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.